Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Completed · Phase 3

Conditions studied: Neovascular Age-related Macular Degeneration

In brief

The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.

Key facts

Study ID

NCT00964795

Run by

Regeneron Pharmaceuticals

People needed

323

Starts

2009-12-01

Expected to finish

2013-08-01

Last updated by the study team

2015-03-23

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in Study VGFT-OD-0605 through week 96.
• In the opinion of the investigator, the study eye has neovascular AMD and may continue to require treatment.

You may not qualify if…

• Presence of any condition that would jeopardize the patient's participation in this study.
• Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.

Where it is running

• Study site — Phoenix (2 Locations), Arizona, United States
• Study site — Tucson (2 Locations), Arizona, United States
• Study site — Arcadia, California, United States
• Study site — Beverly Hills, California, United States
• Study site — Campbell, California, United States
• Study site — Fresno, California, United States
• Study site — Fullerton, California, United States
• Study site — La Jolla, California, United States
• Study site — Loma Linda, California, United States
• Study site — Mountain View, California, United States
• Study site — Oakland, California, United States
• Study site — Orange, California, United States
• Study site — Palm Desert, California, United States
• Study site — Sacramento, California, United States
• Study site — San Mateo, California, United States
• Study site — Santa Ana, California, United States
• Study site — Torrance, California, United States
• Study site — Westlake Village, California, United States
• Study site — Yorba Linda, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Denver (2 Locations), Colorado, United States
• Study site — Bridgeport, Connecticut, United States
• Study site — New Haven, Connecticut, United States
• Study site — New London, Connecticut, United States
• Study site — Birmingham (2 Locations), Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.